EU Commission opens antitrust probe into Sanofi's flu vaccine campaign

The European Commission opened an antitrust investigation into Sanofi over allegations it ran a misleading marketing campaign for its Efluelda flu vaccine while disparaging CSL Seqirus’s Fluad in France and Germany. The probe follows unannounced raids on Sanofi offices in September 2025, and the company says it believes it complied with applicable rules and will cooperate. The case could pressure Sanofi in two key European markets where the Commission says it holds a dominant position.

Analysis

This is less about the fine than about the fragility of Sanofi’s moat in a mature vaccine category. When a dominant incumbent is accused of “comparative” marketing abuse, the real risk is not an immediate earnings hit but a widening of the competitive aperture: procurement teams, pharmacists, and public payers become more willing to trial alternatives, especially in markets where switching costs are low and annual re-bidding already resets share every season. That can translate into a multi-year erosion of pricing power even if any formal penalty is modest.

The second-order effect is asymmetric. CSL Seqirus gains the option value of being framed as the challenger that can win on efficacy rather than marketing, which matters in flu because physician habit and channel trust are sticky until they suddenly are not. A protracted investigation also raises the cost of aggressive promotion across Sanofi’s broader specialty portfolio: compliance teams tend to de-risk campaigns after a headline antitrust probe, which can slow launch velocity and blunt share gains in adjacent products.

Timeline matters. Over days, the stock likely trades on headline overhang and incremental discovery risk from the prior raids; over months, the key catalyst is whether the Commission signals a theory of harm broad enough to imply market abuse rather than isolated messaging missteps. The tail risk for Sanofi is not just a fine, but behavioral remedies that constrain field force conduct or promotional claims in core European markets, which would be more damaging to long-run revenue than a one-time charge.

Consensus may be underestimating how often these cases end in a negotiated “regulatory tax” rather than a dramatic revenue shock. If that is the outcome, the selloff could prove too deep relative to the direct earnings impact, especially for a large-cap pharma with diversified cash flows. But until visibility improves, the market will discount a small probability of a larger structural remedy, and that warrants a tactical risk-off posture.

Key Decisions for Investors

• Short-term: reduce or hedge SNY into investigation headlines; preferred expression is buying 1-3 month put spreads to capture elevated event risk while limiting theta bleed.
• Pair trade: long CSL (or CSL Seqirus exposure if accessible) / short SNY for a 1-3 month horizon; thesis is relative share gain in European flu tenders and promotional credibility, with the spread driven by headline risk rather than fundamentals.
• If owning SNY for defensiveness, overwrite upside via covered calls 2-4 months out; the investigation caps multiple expansion while preserving dividend carry.
• Watch for Commission procedural updates over the next 3-6 months; add back to SNY only if the theory of harm narrows to marketing language rather than dominant-position abuse.